Open an account

Abeona Therapeutics

ABEO · NASDAQ

$4.60+$0.19 (+4.31%)TodayMarket closed ·
Prev close $4.41

About ABEO

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in Cleveland, Ohio and currently employs 226 full-time employees. The firm's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).

Employees
226
Headquarters
CLEVELAND, Ohio
Listed
Sep 19, 1980
Sector
Health Care
Industry
Biotechnology
Website
abeonatherapeutics.com

ABEO key statistics

Market cap
263.05M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.20M
Volume
1.39M
Open price
$4.43
High today
$4.65
Low today
$4.40
52 Week high
$7.65
52 Week low
$4.00

Abeona Therapeutics (ABEO) at a glance

Abeona Therapeutics (ABEO) last traded at $4.60, with a market cap of 263.05M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.40 and $4.65. The current price is 4.5% above the day's low and 1.0% below its high.

Volume so far is 1.39M shares, in line with the average of 1.20M shares a day.

Over the past year Abeona Therapeutics has ranged from $4.00 to $7.65, and now sits 16% of the way up that range.

Abeona Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.35 per share against an estimate of -$0.2346.

The average analyst price target is $19.25, 318.5% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $19.25
Low
$14.14
Now
$4.60
High
$31.50

ABEO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 45.0% on average.

  1. Q3 FY24: reported -$0.63 per share against an estimate of -$0.4114
  2. Q4 FY24: reported -$0.14 per share against an estimate of -$0.3587
  3. Q1 FY25: reported -$0.24 per share against an estimate of -$0.3716
  4. Q2 FY25: reported -$0.53 per share against an estimate of -$0.3893
  5. Q3 FY25: reported -$0.10 per share against an estimate of -$0.2958
  6. Q4 FY25: reported -$0.37 per share against an estimate of -$0.3628
  7. Q1 FY26: reported -$0.30 per share against an estimate of -$0.3628
  8. Q2 FY26: reported -$0.35 per share against an estimate of -$0.2346

ABEO news

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

  • Dylan Berman

    Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week

  • Press releaseBusiness Wire

    ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

Similar companies

Companies in the same industry as Abeona Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.